PMEF
MYGN icon

Point72 Middle East FZE’s Myriad Genetics MYGN Stock Holding History

Point72 Middle East FZE’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-25,120
Closed -$403K – 1744
2023
Q3 		$403K Buy
+25,120
New +$478K 0.01% 861
2023
Q1 		– Sell
-5,636
Closed -$81.8K – 2013
2022
Q4 		$81.8K Buy
+5,636
New +$105K ﹤0.01% 1334

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Point72 Middle East FZE's MYGN Position: Q4 2023 in Review

Point72 Middle East FZE sold out of Myriad Genetics (MYGN) in Q4 2023, closing a stake of 25,120 shares — an estimated $403K sold.

Point72 Middle East FZE first reported a position in MYGN in Q4 2022 and held it in 2 quarters. The position peaked at $403K in Q3 2023. 194 funds tracked by Wall St. Rank hold MYGN as of Q4 2023.

  • Point72 Middle East FZE reported no remaining Myriad Genetics position as of Q4 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 25,120 Myriad Genetics shares in Q4 2023, an estimated $403K.
  • Point72 Middle East FZE first reported a position in Myriad Genetics in Q4 2022 and held it in 2 quarters.
  • Point72 Middle East FZE's Myriad Genetics position peaked at $403K in Q3 2023.
  • 194 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.